Sydney Lupkin
Stories
-
Health Care
A website sold patients obesity drugs at affordable rates. Now they're paying the price
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
-
National
How safe is your weed? Patchy regulations may leave contaminants in the weed supply
Millions of Americans use cannabis and would like to think the products they buy are safe. But regulation is state by state and full of holes. NPR's new series digs into the risks and solutions.
-
Health
The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.
-
Politics
RFK Jr. plans to keep a financial stake in lawsuits against the drugmaker Merck
RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, according to new filings with the Office of Government Ethics.
-
Health
Medicare targets 15 more drugs for price negotiations -- including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
-
Health
Drugmakers hiked prices for hundreds of drugs in early January
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including Ozempic, drugs for HIV, cancer and many others.
-
Health
FDA declares the shortage of obesity drug Zepbound has ended. The results are complicated
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
-
Medical Treatments
Consultations for obesity drug prescriptions are way up over 2023, survey finds
Appointments with health professionals for obesity drug consultations are way up, according to data from Zocdoc, a provider of scheduling services.
-
Health Care
Weight loss drugs could soon be covered by Medicare and Medicaid
The Biden administration is looking to extend Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound. Weight loss drugs are now excluded from mandatory coverage.
-
Health
Drugmakers and pharmacists battle over who gets to make obesity drugs
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.